| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_238a0cbb4d846151b3a4844bad7f9879
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bceb71676971f1383ae2a7e5ccaa7da |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2013-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53e9c3eedeb1b43cd1c408ad289f7aa3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7d852c434d9eb38b0e7f0a9ea61e7b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43cbe720b7551aee5e6d18e8bbecd6d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d338e08ea76f514f6fe5cec326992504 |
| publicationDate |
2021-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2809738-T3 |
| titleOfInvention |
Crystalline forms of an androgen receptor modulator |
| abstract |
A crystalline Form A of 4- [7- (6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro [3.4] oct-5-yl] -2-fluoro -N-methylbenzamide showing at least one of: (a) an X-ray powder diffraction pattern (XRPD) with characteristic peaks at 4.8 ± 0.1º 2-Theta, 7.1 ± 0.1º 2- Theta, 14.2 ± 0.1 º 2-Theta, 16.3 ± 0.1º 2-Theta, 20.1 ± 0.1º 2-Theta; (b) unit cell parameters according to the following at -173 ° C: ** Table ** and optionally (c) the same X-ray powder diffraction pattern (XRPD) as (a) after storage at 40 ° C and 75% RH for at least one week; or (d) a DSC thermogram with an endotherm having a starting temperature at 108-120 ° C and a peak at 133-135 ° C; (e) combinations thereof. |
| priorityDate |
2012-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |